See selection of talks and videos featuring the ERGO team and the work we doGo to page
ERGO (Epidemic diseases Research Group Oxford)
The overarching aim of the Epidemic diseases Research Group Oxford (ERGO) is to reduce the health and socioeconomic impact of emerging and epidemic infections by conducting and enabling clinical research on emerging and epidemic infections.Learn more
PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics)
PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics) is an EU funded network for harmonised large-scale clinical research studies on infectious diseases.Learn more
UK-PHRST (UK Public Health Rapid Support Team)
The UK-PHRST, funded by UK aid from the Department of Health and Social Care, supports low- and middle-income countries in investigating and responding to disease outbreaks and conducts research to improve our response to future epidemics.Learn more
ALERRT (The African coaLition for Epidemic Research, Response and Training)
The African coaLition for Epidemic Research, Response and Training (ALERRT) is a multi-disciplinary consortium building a patient-centered clinical research network to respond to epidemics across sub-Saharan AfricaLearn more
The Global Health Network Conference 2022
Did you miss The Global Health Network Conference 2022? To catch up, watch the replay from here.Learn more
RECOVERY: Randomised Evaluation of COVID-19 Therapy
Led by ERGO's Peter Horby, this national clinical trial aims to identify treatments that may be beneficial for adults hospitalised with confirmed COVID-19. The trial is being conducted in over 130 NHS hospitals across the UK. Adult patients who have been admitted to hospital with COVID-19 are being invited to take part, and more information can be found at https://www.recoverytrial.net/.
Watch Peter discussing the trial on our Talks and Videos page.
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Character
Background Studies of patients admitted to hospital with COVID-19 have found varying mortality outcomes associated with underlying respiratory conditions and inhaled corticosteroid use. Using data from a national, multicentre, ...
Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study
Background Lassa fever is a viral haemorrhagic fever endemic in parts of west Africa. New treatments are needed to decrease mortality, but pretrial reference data on the disease characteristics ...
Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19
While it is now widely accepted that host inflammatory responses contribute to lung injury, the pathways that drive severity and distinguish coronavirus disease 2019 (COVID-19) from other viral lung diseases ...
Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
Dexamethasone can reduce mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the potential number of lives saved and life years ...
What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic review
Although the majority of people with Covid-19 will experience mild to moderate symptoms and will recover fully, there is now increasing evidence that a significant proportion will experience persistent symptoms ...
Dexamethasone reduces mortality in hospitalised patients with respiratory complications of COVID-19
Professor Peter Horby and Professor Martin Landray, chief investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial, said: In March this year, RECOVERY was established as a randomised clinical trial to test a range of potential treatments for COVID-19, ... Read more